EV Collaboration Opportunity to expand regional distribution and direct sales through partnerships with Izon’s existing distributors like Atlantis Bioscience in Singapore, leveraging ASPEV 2025 presence to drive initial orders and demonstrate practical EV isolation workflows.

Clinical EV Potential Target biotechs and contract development organizations focused on extracellular vesicle diagnostics and therapeutics, offering scalable qEV isolation workflows and customised bioprocessing services to accelerate preclinical to clinical transition.

Platform Upsell Cross-sell complementary Exoid TRPS characterization systems alongside qEV columns to existing EV and lipid nanoparticle researchers, providing end-to-end particle isolation and sizing that supports quality control and regulatory documentation.

Geographic Reach Leverage global offices (New Zealand, France, US) to pursue multinational customers and regional pilots, emphasizing local support, training, and service packages to reduce adoption barriers for EV-centric laboratories.

Product Expansion Highlight ongoing product evolution such as Gen 2 qEV columns and 1 mL optimized variants to position Izon as a continuously improving supplier, inviting early-access programs and pilot projects with research labs transitioning to higher throughput EV research.